procedures used to diagnose toxic hepatitis include:

Physical exam.

medical history.

Blood tests.

Your doctor may order blood tests that look for high levels of certain liver enzymes. ...

Imaging tests. ...

Liver biopsy.

toxicity occurs through mitochondrial damage resulting in lactic acidosis and hepatic steatosis. Protease inhibitors induce DILI in 6–11% of patients, but the incidence is significantly increased in HBV or HCV co-infections and alcohol consumption

combine radiological, laboratory and clinical assessments. At least do liver function and liver cell injury markers, examine the patient and have an ultrasound.

Collateral damage to the liver in cancer therapy is not uncommon. Hepatotoxicity from chemotherapy occurs frequently in an unpredictable or idiosyncratic fashion and preexisting liver disease increases this risk. The pattern of presentation can vary from that of an inflammatory hepatitis, cholestasis, steatosis, and finally a vascular presentation as hepatic VOD. The severity ranges from asymptomatic liver function test elevation, acute liver failure, or a progressive fibrosis culminating in end stage liver disease. Various groups have produced liver toxicity classifications that lay out dose modification guidelines for various chemotherapeutic agents. Nevertheless, with knowledge and caution, many potential side effects and serious damage to the recipient can be avoided.

First, broad awareness about oncology drugs and their side effects. Second, Broad knowledge of drug induced hepatitis both at acute and chronic level. Having such knowledge, Regular assessment of patients along with patient history plus timely clinical markers identification for liver functioning will not only be helpful to prevent hepatotoxicity induced by anti-cancer drugs in patients, but also provide new strategic way to handle the mild to worse situation.